.Pharmacolibrary.Drugs.ATC.A.A10AC30 .Pharmacolibrary.Drugs.ATC.A.A10AC30| name: | InsulinDegludecAndLiraglutide |
| ATC code: | A10AC30 | route: | subcutaneous |
| n-compartments | 1 |
A fixed-ratio combination of insulin degludec (a long-acting basal insulin analog) and liraglutide (a GLP-1 receptor agonist), marketed as Ideglira or Xultophy, used for the treatment of type 2 diabetes mellitus in adults to achieve glycemic control when oral antidiabetic agents or insulin alone do not provide adequate control. Approved and in use in multiple countries.
Pharmacokinetic parameters following subcutaneous administration of the combination product (IDegLira) in adults with type 2 diabetes mellitus (median age ~57 years, both sexes included).